Xencor (XNCR) Non-Current Deffered Revenue (2013 - 2024)

Xencor's (XNCR) quarterly Non-Current Deffered Revenue came in at $94.1 million in Q3 2024, down 9.58% on a QoQ basis from $104.1 million in Q2 2024.

Xencor (XNCR) Non-Current Deffered Revenue (2013 - 2024) Analysis & Trends

Xencor (XNCR) has 8 years of Non-Current Deffered Revenue data on file, last reported at $94.1 million in Q3 2024.

On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $94.1 million in Q3 2024; TTM through Sep 2024 was $94.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $1.9 million, up 58.6% from the prior year.
Non-Current Deffered Revenue for Q3 2024 stood at $94.1 million, down from $104.1 million in the prior quarter.
Over the last five years, Non-Current Deffered Revenue for XNCR reached as high as $104.1 million in Q2 2024 and fell as low as $94.1 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Xencor	1.49 Bn	1.11 Bn	-	-

Download Data